自制活化凝血酶原复合物的安全性和有效性评价

潘旭 ,  黄雨薇 ,  毛烈火 ,  孙盼 ,  李长清 ,  杜晞 ,  马莉

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (8) : 1004 -1011.

PDF (3019KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (8) : 1004 -1011. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.08.002
论著

自制活化凝血酶原复合物的安全性和有效性评价

作者信息 +

Preliminary evaluation of the safety and efficacy of a self-prepared activated prothrombin complex concentrate

Author information +
文章历史 +
PDF (3090K)

摘要

目的 评价自制活化凝血酶原复合物(activated Prothrombin Complex Concentrate,aPCC)的体外促凝有效性和体内潜在致血栓风险。方法 按 0. 5 IU/ mL 血浆剂量给药,通过体外实验,将自制 aPCC 浓缩物加入 FⅧ抑制物模拟血浆中,利用自动标准化凝血酶生成试验(Calibrated automated thrombin generation,CAT)、凝血酶原时间(pro-thrombin time,PT)、活化部分凝血活酶时间(activated partial thromboplastin time,APTT)、凝血酶时间(thrombin time, TT)及纤维蛋白原(fibrinogen,Fib)检测,以正常血浆和 FEIBA®作为对照评价自制 aPCC 浓缩物的促凝能力;通过动物实验,将自制 aPCC 浓缩物经颈静脉注射入大鼠体内,用 FeCl3 贴片诱导颈动脉血栓形成,再利用激光散斑血流成像监测观察大鼠颈动脉血栓生成情况,并采集大鼠血浆进行 CAT、PT、APTT、TT 及 Fib 检测,并将生理盐水和 FEIBA®做为对照评价自制 aPCC 浓缩物的潜在致血栓风险。结果 抑制物血浆中加入 aPCC 后,显著降低了抑制物血浆的 APTT、PT(均 P<0. 001)。 FEIBA®和自制 aPCC 的 APTT、PT 值无显著差异(P>0. 05)。 CAT 检测结果显示,抑制物血浆加入 aPCC 后,内源性凝血酶生成潜力(ETP)与凝血酶峰值(Peak)水平显著升高(P<0. 001),且高于正常血浆(P<0. 001),而自制 aPCC 和 FEIBA®的 ETP 无显著差异(P>0. 05)。 大鼠颈动脉血流成像监测结果显示,与 FEIBA®相比,自制 aPCC 形成的血栓较小、稳定性差,均发生自溶,大鼠颈动脉血流恢复情况较好。结论 自制 aPCC 与 FEIBA®一样能较好恢复抑制物血浆的凝血能力,且致血栓风险性较低。

Abstract

Objective To evaluate the in vitro procoagulant efficacy and in vivo potential thrombogenic risk of self-prepared activated prothrombin complex concentrate (aPCC). Methods The preparation was administered at a dose of 0. 5 IU per milliliter of plasma. For in vitro assays, the self-prepared aPCC concentrate was added to plasma spiked with factor Ⅷ (FⅧ) inhibitors. Calibrated automated thrombin generation (CAT), prothrombin time (PT), activated partial thrombo-plastin time (APTT), thrombin time (TT), and fibrinogen (Fib) quantification were performed. Normal saline and FEIBA® were set as controls to evaluate the procoagulant capacity of the self-prepared aPCC concentrate. For in vivo animal studies, the self-prepared aPCC concentrate was injected into rats via the jugular vein. A ferric chloride (FeCl3) filter pa-per patch was applied to induce carotid arterial thrombosis. Laser speckle blood flow imaging was used to continuously moni-tor thrombus formation in the rat carotid artery. Plasma samples were collected from rats for CAT, PT, APTT, TT and Fib testing, with normal saline and FEIBA® as controls to evaluate the potential thrombogenic risk of the self-prepared aPCC concentrate. Results Supplementation with aPCC significantly shortened APTT and PT values in inhibitor-spiked plasma (all P< 0. 001). There were no statistically significant differences in APTT and PT between FEIBA® and self-prepared aPCC (P>0. 05). CAT results demonstrated that adding aPCC to inhibitor-containing plasma markedly increased endoge-nous thrombin potential (ETP) and peak thrombin concentration (Peak) (P<0. 001), with both parameters higher than those of normal plasma (P<0. 05). No significant intergroup difference in ETP was observed between self-prepared aPCC and FEIBA® (P>0. 05). Carotid blood flow imaging in rats revealed that, compared with FEIBA®, thrombi induced by self-prepared aPCC were smaller and less stable, and all underwent spontaneous lysis, accompanied by better restoration of ca-rotid blood perfusion. Conclusion The self-prepared aPCC restores coagulation function in inhibitor-spiked plasma to a comparable extent as FEIBA®, while exhibiting a lower thrombogenic risk.

关键词

活化凝血酶原复合物(aPCC) / FⅧ旁路活性(FEIBA) / 自动标准化凝血酶生成试验(CAT) / 血栓风险

Key words

activated prothrombin complex concentrate (aPCC) / factor eight bypassing activity (FEIBA) / calibrated automated thrombin generation (CAT) / thrombotic risk

引用本文

引用格式 ▾
潘旭,黄雨薇,毛烈火,孙盼,李长清,杜晞,马莉. 自制活化凝血酶原复合物的安全性和有效性评价[J]. 中国输血杂志, 2026, 39(8): 1004-1011 DOI:10.13303/j.cjbt.issn.1004-549x.2026.08.002

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

SAHIN T K, ALADAG E, SETTERZADE E, et al. Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor: Case report and review of the literature[J].Medicine (Baltimore), 2020, 99(26):e20851.

[2]

MAHLANGU J, OLDENBURG J, PAZ-PRIEL I, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors[J].N Engl J Med, 2018, 379(9):811-822.

[3]

YOUNG G, LIESNER R, CHANG T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors[J].Blood, 2019, 134(24):2127-2138.

[4]

PIPE S W, SHIMA M, LEHLE M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HA-VEN 4): a multicentre, open-label, non-randomised phase 3 study[J].Lancet Haematol, 2019, 6 (6): e295-e305.

[5]

TEITEL J M. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors[J].Transfus Apher Sci, 2018, 57(4):466-471.

[6]

KEMPTON C L, MEEKS S L. Toward optimal therapy for inhibitors in hemophilia[J]. Blood, 2014, 124 (23):3365-3372.

[7]

TELLIER Z, ANDRé M H, POLACK B. Management of haemophilia A-inhibitor patients:clinical and regulatory perspectives[J].Clin Rev Allergy Immunol, 2009, 37 (2):125-134.

[8]

HOFFMAN M, DARGAUD Y. Mechanisms and monitoring of bypassing agent therapy[J].J Thromb Haemost, 2012, 10(8):1478-1485.

[9]

KJALKE M, MADS KJELGAARD-HANSEN, ANDERS-EN S,et al. Thrombin generation potential in the pres-ence of concizumab and rFVIIa, APCC, rFⅧ, or rFIX: In vitro and ex vivo analyses[J].J Thromb Haemost, 2021, 19(7):1687-1696.

[10]

VARADI K, TANGADA S, LOESCHBERGER M, et al. Pro-and anticoagulant factors facilitate thrombin gen-eration and balance the haemostatic response to FEIBA® in prophylactic therapy[J].Haemophilia, 2016, 22 (4):615-624.

[11]

OLDENBURG J, MAHLANGU J N, KIM B, et al. Emi-cizumab Prophylaxis in Hemophilia A with Inhibitors[J].The New England journal of medicine, 2017, 377 (9):809-818.

[12]

HARTMANN R. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents[J].J Thromb Haemost, 2018,16(8):1580-1591.

[13]

KIZILOCAK H, ELIZABETH M C, WEE C P, et al. Comparison of bypassing agents in patients on emicizum-ab using global hemostasis assays[J].Haemophilia, 2021, 27(1):164-172.

[14]

KIZILOCAK H, ELIZABETH M C, MALVAR J, et al. Safety of FEIBA and emicizumab (SAFE):Dose escala-tion study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemo-philia A patients on emicizumab[J]. Haemophilia, 2023, 29(1):100-105.

[15]

CROMWELL C, ALEDORT L M. FEIBA:a prohemosta-tic agent[J].Semin Thromb Hemost, 2012, 38 (3): 265-267.

[16]

EHRLICH H J, HENZL M J, GOMPERTS E D. Safety of factor Ⅷ inhibitor bypass activity (FEIBA):10-year compilation of thrombotic adverse events[J].Haemo-philia, 2002, 8(2):83-90.

[17]

GROTTKE, O, BRAUNSCHWEIG T, SPRONK H M, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury[J].Blood, 2011, 118(7):1943-1951.

[18]

GHOSH, S,KREGE W, DOERR B, et al. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models[J].PLoS One, 2021, 16(10):e0258192.

[19]

INGERSLEV J, SøRENSEN B. Parallel use of by-pass-ing agents in haemophilia with inhibitors:a critical review[J].Br J Haematol, 2011, 155(2):256-262.

[20]

BRIEN L. Anticoagulant Medications for the Prevention and Treatment of Thromboembolism[J].AACN Adv Crit Care, 2019, 30(2):126-138.

[21]

黄雨薇,赵娅菲,叶刚,等. 自制活化凝血酶原复合物 的主要药效成分分析[J].中国生物制品学杂志, 2025, 38(3):312-317.

[22]

HUANG Y W, ZHAO Y F, YE G, et al. Analysis of the primary active pharmaceutical ingredients in self-formula-ted activated prothrombin complex[J].Chinese Journal of Biological Products, 2025,38(3):312-317.

[23]

DINESS V, BREGENGAARD C, ERHARDTSEN E, et al. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model[J].Thromb Res, 1992, 67(2):233-241.

[24]

ELG M, CARLSSON S, GUSTAFSSON D. Effect of ac-tivated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor[J].Thromb Res, 2001, 101(3):145-157.

[25]

[24] MAJUMDER R. Not so fast, antithrombin![J]. Blood, 2023, 141(16):1907-1908.

基金资助

四川省科技计划项目,活化凝血酶原复合物制品的研究与开发(2021YFS0056)

AI Summary AI Mindmap
PDF (3019KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉